Indivior Latest Indivior’s miracle drug wears off Features Indivior’s opioid addiction treatment has been exposed to generic competition. Can the drugmaker fight back? Alice Gråhns reports. Features If you’d invested in: Indivior and Next Features Drugmaker Indivior is on the up, while retailer Next, once a favourite with investors, has lost its way. By Ben Judge Published 24 February 17 Features
